On the stock market since 2022, it operates in the world of health and science. It has 13 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 17% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 17 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $36.00 — 53% above today’s price.
A loss of $26.4M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.2 years. After that, the company needs to find new money.
On our five-subject report card, NVCT sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NVCT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (50/100) says the stock isn’t cheap.